Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Debt / NOTE 0.250% 3/0
-
Number of holders
-
53
-
Total 13F principal, excl. options
-
676,406,024
-
Principal change
-
-304,196,171
-
Total reported value, excl. options
-
$656,553,304
-
Value change
-
-$264,456,865
-
Number of buys
-
19
-
Number of sells
-
-28
-
Price
-
$0.9714
Significant Holders of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 as of Q4 2022
59 filings reported holding 40637HAD1 - HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 as of Q4 2022.
HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 has 53 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $676,406,024 of principal
.
Largest 10 bondholders include Voya Investment Management LLC ($233,750,000 of principal), Davidson Kempner Capital Management LP ($79,311,000 of principal), Invesco Ltd. ($63,900,000 of principal), CAMDEN ASSET MANAGEMENT L P /CA ($57,961,000 of principal), AVIVA PLC ($24,100,000 of principal), BlackRock Inc. ($22,950,000 of principal), CITIGROUP INC ($20,165,000 of principal), STATE STREET CORP ($19,545,000 of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($17,000,000 of principal), and AMERIPRISE FINANCIAL INC ($14,000,000 of principal).
This table shows the top 53 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.